Forty Years Later-Complications and Mortality Associated with Cultured Epithelial Autografts in Burn Patients: A Systematic Review.
6 affiliations
- 1Pediatric Burn Center, Division of Plastic and Reconstructive Surgery, Children's Skin Center, Department of Surgery, University Children's Hospital Zurich, University of Zurich, Lenggstrassse 30, 8008 Zurich, Switzerland.
- 2Department of Pediatric Surgery, University Children's Hospital Zurich, University of Zurich, Lenggstrasse 30, 8008 Zurich, Switzerland.
- 3Children's Research Center (CRC), University Children's Hospital Zurich, University of Zurich, Lenggstrasse 30, 8008 Zurich, Switzerland.
- 4Regenerative Therapy Unit, Service of Plastic, Reconstructive and Aesthetic Surgery and Hand Surgery, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland.
- 5Children and Adolescent Surgery Service, Lausanne University Hospital, University of Lausanne, 1015 Lausanne, Switzerland.
- 6Department of Pediatric Surgery, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.
Abstract
Cultured epithelial autografts (CEAs) have been used for more than 40 years in the setting of extensive total body surface area (TBSA) burns. The development and clinical implementation of cultured epidermal autografts and, subsequently, combined cultured dermo-epidermal autografts (CDEAs) have provided an essential adjunctive treatment option. Over the past five decades, numerous studies have reported on their clinical application. CEAs are manufactured from autologous epidermal cells that are expanded in vitro and assembled into sheet grafts suitable for transplantation. While substantial literature exists regarding their clinical use, data specifically addressing treatment-related complications remain scarce. This systematic review aims to comprehensively synthesize the available evidence on sheet-type CEA/CDEA use in burn patients, with a particular focus on complications, tumorigenicity, and mortality. A systematic literature search was conducted in 2023 across five electronic databases (Cochrane on 31 May 2023, Embase on 31 May 2023, Ovid Medline on 31 May 2023, Scopus on 1 June 2023, and Web of Science on 1 June 2023) to identify studies reporting on the use of CEAs in burn patients. Search terms included combinations of "cultured," "epithelial," "autografts," "take rate," "mortality," and "skin cancer." Eligible studies were human clinical studies involving burn patients treated with sheet-type CEA or CDEA, published in English, French, or German. Exclusion criteria comprised studies involving allogeneic materials, in vitro or animal studies, and commentaries and editorials. Efficacy endpoints included complications, tumorigenicity, and mortality outcomes in CEA-treated patients. Risk of bias was assessed for each included study using the modified Downs and Black checklist and graded according to Hooper et al. Seventy studies contributing 72 patient cohorts published between 1984 and 2023 met inclusion criteria, encompassing a total of 2091 patients from all five continents. The mean graft take rate was 64% in adults and 70% in pediatric patients. Complication events and mortality data are described in the corresponding tables. This systematic review represents the first comprehensive synthesis specifically addressing complications, tumorigenicity, and mortality in burn patients treated with CEAs. The reported adverse events must be interpreted within the context of the high morbidity associated with extensive burn injuries. The observed mortality and number of complications appear primarily related to burn severity rather than to CEA use itself. No adverse events were identified that could be specifically attributed to CEAs. Interpretation of these findings is limited by the clinical and methodological heterogeneity of the included studies. In patients with extensive burn injuries, the use of CEAs is associated with a relatively low number of complications and appears to be a safe and clinically justified treatment option. This study received no internal or external funding. This study is referenced in the PROSPERO Database for systematic reviews under the number CRD420251040971.
Related
- Microvascular and Macrovascular Complications and Their Associated Risk Factors Among Patients with Type 2 Diabetes in Saudi Arabia: A Systematic Review and Meta-Analysis
- Associated factors for in-hospital mortality in patients with fulminant myocarditis: a systematic review and meta-analysis
- Factors associated with mortality in patients with atrial fibrillation: an umbrella review of systematic reviews and meta-analyses
- Site-Specific Survival and Complications of Extra-oral Craniofacial Implants in Irradiated and Non-irradiated Patients: A Systematic Review and Meta-Analysis
- Local infiltration anesthesia (anterior field block) vs. general anesthesia for thyroidectomy: effects on operative time, complications, and cost—a GRADE-assessed systematic review and meta-analysis with subgroup analysis
BibTeX
@article{dontschev2026forty,
title = {{Forty Years Later-Complications and Mortality Associated with Cultured Epithelial Autografts in Burn Patients: A Systematic Review.}},
author = {Alexandre Dontschev and Vivienne Woodtli and Clemens Maria Schiestl and Kathrin Neuhaus and Philippe Abdel-Sayed and Anthony de Buys Roessingh and Christoph Moor and Ueli Moehrlen and Sophie Böttcher},
journal = {Bioengineering (Basel, Switzerland)},
year = {2026},
month = sep,
doi = {10.3390/bioengineering13101096},
url = {https://europepmc.org/article/MED/42938951},
note = {CC BY},
}
RIS
TY - JOUR
TI - Forty Years Later-Complications and Mortality Associated with Cultured Epithelial Autografts in Burn Patients: A Systematic Review.
AU - Alexandre Dontschev
AU - Vivienne Woodtli
AU - Clemens Maria Schiestl
AU - Kathrin Neuhaus
AU - Philippe Abdel-Sayed
AU - Anthony de Buys Roessingh
AU - Christoph Moor
AU - Ueli Moehrlen
AU - Sophie Böttcher
PY - 2026
DA - 2026/09/22
JO - Bioengineering (Basel, Switzerland)
DO - 10.3390/bioengineering13101096
UR - https://europepmc.org/article/MED/42938951
AB - Cultured epithelial autografts (CEAs) have been used for more than 40 years in the setting of extensive total body surface area (TBSA) burns. The development and clinical implementation of cultured epidermal autografts and, subsequently, combined cultured dermo-epidermal autografts (CDEAs) have provided an essential adjunctive treatment option. Over the past five decades, numerous studies have reported on their clinical application. CEAs are manufactured from autologous epidermal cells that are expanded in vitro and assembled into sheet grafts suitable for transplantation. While substantial literature exists regarding their clinical use, data specifically addressing treatment-related complications remain scarce. This systematic review aims to comprehensively synthesize the available evidence on sheet-type CEA/CDEA use in burn patients, with a particular focus on complications, tumorigenicity, and mortality. A systematic literature search was conducted in 2023 across five electronic databases (Cochrane on 31 May 2023, Embase on 31 May 2023, Ovid Medline on 31 May 2023, Scopus on 1 June 2023, and Web of Science on 1 June 2023) to identify studies reporting on the use of CEAs in burn patients. Search terms included combinations of "cultured," "epithelial," "autografts," "take rate," "mortality," and "skin cancer." Eligible studies were human clinical studies involving burn patients treated with sheet-type CEA or CDEA, published in English, French, or German. Exclusion criteria comprised studies involving allogeneic materials, in vitro or animal studies, and commentaries and editorials. Efficacy endpoints included complications, tumorigenicity, and mortality outcomes in CEA-treated patients. Risk of bias was assessed for each included study using the modified Downs and Black checklist and graded according to Hooper et al. Seventy studies contributing 72 patient cohorts published between 1984 and 2023 met inclusion criteria, encompassing a total of 2091 patients from all five continents. The mean graft take rate was 64% in adults and 70% in pediatric patients. Complication events and mortality data are described in the corresponding tables. This systematic review represents the first comprehensive synthesis specifically addressing complications, tumorigenicity, and mortality in burn patients treated with CEAs. The reported adverse events must be interpreted within the context of the high morbidity associated with extensive burn injuries. The observed mortality and number of complications appear primarily related to burn severity rather than to CEA use itself. No adverse events were identified that could be specifically attributed to CEAs. Interpretation of these findings is limited by the clinical and methodological heterogeneity of the included studies. In patients with extensive burn injuries, the use of CEAs is associated with a relatively low number of complications and appears to be a safe and clinically justified treatment option. This study received no internal or external funding. This study is referenced in the PROSPERO Database for systematic reviews under the number CRD420251040971.
SN - 2306-5354
ER -